디지털 병리학 시장 규모, 점유율 및 동향 분석 보고서 : 제품별, 유형별, 용도별, 치료 영역별, 최종 용도별, 부문별 예측(2026-2033년)

Digital Pathology Market Summary

The global digital pathology market size was estimated at USD 1.53 billion in 2025 and is projected to reach USD 2.97 billion by 2033, growing at a CAGR of 8.6% from 2026 to 2033. This is attributed to rising prevalence of cancer, increasing focus on improving the efficiency of workflow, and growing demand for faster diagnostic tools.

Moreover, rising investments in healthcare aided by major key players operating in the market focusing on new launches, increasing adoption of telepathology, and an increasing focus on drug discovery and precision medicine is propelling the market growth.

The digital pathology industry is predominantly driven by the growing prevalence of chronic diseases such as cancer. As a consequence of the high prevalence of cancer, pathologists require pathology data that can facilitate customizing of therapies for patients. Therefore, digital pathology is increasingly preferred by pathologists, as it accelerates the diagnosis rate, enhances diagnostic accuracy, and provides therapeutic recommendations to improve patient outcomes. For instance, a 2024 study published in Breast Cancer Research highlights the application of deep learning models such as ResNet50, Transformer, and Hover-net in enhancing image enhancement, segmentation, and classification for breast cancer diagnosis. Such instances signify the growth potential of the market.

Rising adoption of healthcare IT solutions is fueling the demand for digital pathology solutions. Organizations are increasingly implementing them to cut costs, streamline processes, overcome resource bottlenecks, and facilitate efficient content sharing. A growing necessity for collaborations and the expanding use of digital documentation across various scientific disciplines also drives the demand. In addition, factors such as heightened adoption to enhance laboratory efficiency, a surge in teleconsultations, and increased applications in companion diagnostics and drug discovery are expected to contribute to the market's growth.

Additionally, AI is being leveraged to enhance the analysis of digital images. Previously, pathologists had to identify regions of interest within tissue samples manually, but AI is now automating this process. This shift reduces the reliance on manual labor, minimizing the risk of human error and promoting greater automation in pathology practices.

Global Digital Pathology Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global digital pathology market based on product, application, therapeutic area, end use, and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Software
• Device
  • Scanners
  • Slide Management Systems
• Storage System
• Type Outlook (Revenue, USD Million, 2021 - 2033)
• Human Pathology
• Veterinary Pathology
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Drug Discovery & Development
• Academic Research
• Disease Diagnosis
  • Cancer Cell Detection
  • Others
• Therapeutic Area Outlook (Revenue, USD Million, 2021 - 2033)
• Oncology
• Cardiovascular
• Neurology
• Others (Including dermatology, infectious diseases, gastrointestinal, etc.)
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals
• Biotech & Pharma Companies
• Diagnostic Labs
• Academic & Research Institutes
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Russia
  • Spain
  • Netherlands
  • Switzerland
  • Sweden
  • Denmark
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Indonesia
  • Thailand
  • Australia
  • South Korea
  • Philippines
  • Malaysia
  • Singapore
• Latin America
  • Brazil
  • Argentina
  • Mexico
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Turkey
  • Iran
  • United Arab Emirates
  • Israel
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Type
  • 1.2.3. Application
  • 1.2.4. Therapeutic Area
  • 1.2.5. End Use
• 1.3. Regional scope
• 1.4. Estimates and forecasts timeline
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased database
  • 1.6.2. GVR's internal database
  • 1.6.3. Secondary sources
  • 1.6.4. Primary research
  • 1.6.5. Details of primary research
• 1.7. Information or Data Analysis
  • 1.7.1. Data analysis models
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity flow analysis
• 1.10. List of Secondary Sources
• 1.11. List of Primary Sources
• 1.12. Objectives

Chapter 2. Executive Summary

• 2.1. Digital Pathology Market Snapshot
• 2.2. Digital Pathology Market Segment Snapshot
• 2.3. Digital Pathology Market Competitive Landscape Snapshot

Chapter 3. Digital Pathology Market: Component Estimates & Trend Analysis

• 3.1. Market Dynamics
  • 3.1.1. Market driver analysis
    • 3.1.1.1. Increasing prevalence of chronic diseases
    • 3.1.1.2. Higher cost-efficiency
    • 3.1.1.3. Rapid technological advancements
    • 3.1.1.4. Increasing demand for integrated healthcare systems and patient-centric care
    • 3.1.1.5. Growing adoption of digital pathology solutions in veterinary care practices
    • 3.1.1.6. Rapid technological advancements in digital pathology solutions in veterinary field
  • 3.1.2. Market restraint analysis
    • 3.1.2.1. Lack of skilled professionals
    • 3.1.2.2. High cost of implementing digital pathology solutions
  • 3.1.3. Market opportunity analysis
  • 3.1.4. Market challenges analysis
  • 3.1.5. Industry Analysis - Porter's Five Forces Analysis
    • 3.1.5.1. Supplier power
    • 3.1.5.2. Buyer power
    • 3.1.5.3. Substitution threat
    • 3.1.5.4. Threat of new entrant
    • 3.1.5.5. Competitive rivalry
  • 3.1.6. PESTEL Analysis
• 3.2. Technology Trend Analysis
• 3.3. Regulatory Framework
• 3.4. Cost Structure Analysis
  • 3.4.1. Cost of implementation
  • 3.4.2. Price erosion analysis
• 3.5. User Perspective Analysis
  • 3.5.1. Consumer behavior analysis
• 3.6. Market Entry Strategies
  • 3.6.1. Competitive strategies
• 3.7. Case Study Insights

Chapter 4. Digital Pathology Market: Product Estimates & Trend Analysis

• 4.1. Global Digital Pathology Market: Product Dashboard
• 4.2. Global Digital Pathology Market: Product Movement Analysis
• 4.3. Global Digital Pathology Market Estimates and Forecasts, By Product, Revenue (USD Million)
• 4.4. Software
  • 4.4.1. Software market estimates and forecasts 2021 to 2033 (USD Million)
• 4.5. Device
  • 4.5.1. Devices market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.5.2. Scanners
    • 4.5.2.1. Scanners market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.5.3. Slide Management System
    • 4.5.3.1. Slide management system market estimates and forecasts 2021 to 2033 (USD Million)
• 4.6. Storage System
  • 4.6.1. Storage system market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Digital Pathology Market: Type Estimates & Trend Analysis

• 5.1. Global Digital Pathology Market: Type Dashboard
• 5.2. Global Digital Pathology Market: Type Movement Analysis
• 5.3. Global Digital Pathology Market Estimates and Forecasts, By Type, Revenue (USD Million)
• 5.4. Human Pathology
  • 5.4.1. Human pathology market estimates and forecasts, 2021 to 2033 (USD Million)
• 5.5. Veterinary Pathology
  • 5.5.1. Veterinary pathology market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 6. Digital Pathology Market: Application Estimates & Trend Analysis

• 6.1. Global Digital Pathology Market: Application Dashboard
• 6.2. Global Digital Pathology Market: Application Movement Analysis
• 6.3. Global Digital Pathology Market Estimates and Forecasts, By Application, Revenue (USD Million)
• 6.4. Drug Discovery & Development
  • 6.4.1. Drug discovery & development market estimates and forecasts, 2021 to 2033 (USD Million)
• 6.5. Academic Research
  • 6.5.1. Academic research market estimates and forecasts, 2021 to 2033 (USD Million)
• 6.6. Disease Diagnosis
  • 6.6.1. Disease diagnosis market estimates and forecasts, 2021 to 2033 (USD Million)
  • 6.6.2. Cancer Cell Detection
    • 6.6.2.1. Cancer cell detection market estimates and forecasts, 2021 to 2033 (USD Million)
  • 6.6.3. Others
    • 6.6.3.1. Others market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 7. Digital Pathology Market: Therapeutic Area Estimates & Trend Analysis

• 7.1. Global Digital Pathology Market: Therapeutic Area Dashboard
• 7.2. Global Digital Pathology Market: Therapeutic Area Movement Analysis
• 7.3. Global Digital Pathology Market Estimates and Forecasts, By Therapeutic Area, Revenue (USD Million)
• 7.4. Oncology
  • 7.4.1. Oncology market estimates and forecasts, 2021 to 2033 (USD Million)
• 7.5. Cardiovascular
  • 7.5.1. Cardiovascular market estimates and forecasts, 2021 to 2033 (USD Million)
• 7.6. Neurology
  • 7.6.1. Neurology market estimates and forecasts, 2021 to 2033 (USD Million)
• 7.7. Others
  • 7.7.1. Others market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 8. Digital Pathology Market: End Use Estimates & Trend Analysis

• 8.1. Global Digital Pathology Market: End Use Dashboard
• 8.2. Global Digital Pathology Market: End Use Movement Analysis
• 8.3. Global Digital Pathology Market Estimates and Forecasts, By End Use, Revenue (USD Million)
• 8.4. Hospitals
  • 8.4.1. Hospitals market estimates and forecasts, 2021 to 2033 (USD Million)
• 8.5. Biotech & Pharma Companies
  • 8.5.1. Biotech & pharma companies market estimates and forecasts, 2021 to 2033 (USD Million)
• 8.6. Diagnostic Labs
  • 8.6.1. Diagnostic labs market estimates and forecasts, 2021 to 2033 (USD Million)
• 8.7. Academic & research institutes
  • 8.7.1. Academic & Research Institutes market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 9. Digital Pathology Market: Regional Estimates & Trend Analysis by Product and End Use

• 9.1. Regional Dashboard
• 9.2. Market Size & Forecasts Trend Analysis, 2021 to 2033
• 9.3. North America
  • 9.3.1. U.S.
    • 9.3.1.1. Key country dynamics
    • 9.3.1.2. Regulatory framework
    • 9.3.1.3. Competitive scenario
    • 9.3.1.4. U.S. market estimates and forecasts, 2021 to 2033 (USD Million)
  • 9.3.2. Canada
    • 9.3.2.1. Key country dynamics
    • 9.3.2.2. Regulatory framework
    • 9.3.2.3. Competitive scenario
    • 9.3.2.4. Canada market estimates and forecasts, 2021 to 2033 (USD Million)
• 9.4. Europe
  • 9.4.1. UK
    • 9.4.1.1. Key country dynamics
    • 9.4.1.2. Regulatory framework
    • 9.4.1.3. Competitive scenario
    • 9.4.1.4. UK market estimates and forecasts, 2021 to 2033 (USD Million)
  • 9.4.2. Germany
    • 9.4.2.1. Key country dynamics
    • 9.4.2.2. Regulatory framework
    • 9.4.2.3. Competitive scenario
    • 9.4.2.4. Germany market estimates and forecasts, 2021 to 2033 (USD Million)
  • 9.4.3. France
    • 9.4.3.1. Key country dynamics
    • 9.4.3.2. Regulatory framework
    • 9.4.3.3. Competitive scenario
    • 9.4.3.4. France market estimates and forecasts, 2021 to 2033 (USD Million)
  • 9.4.4. Italy
    • 9.4.4.1. Key country dynamics
    • 9.4.4.2. Regulatory framework
    • 9.4.4.3. Competitive scenario
    • 9.4.4.4. Italy market estimates and forecasts, 2021 to 2033 (USD Million)
  • 9.4.5. Spain
    • 9.4.5.1. Key country dynamics
    • 9.4.5.2. Regulatory framework
    • 9.4.5.3. Competitive scenario
    • 9.4.5.4. Spain market estimates and forecasts, 2021 to 2033 (USD Million)
  • 9.4.6. Denmark
    • 9.4.6.1. Key country dynamics
    • 9.4.6.2. Regulatory framework
    • 9.4.6.3. Competitive scenario
    • 9.4.6.4. Denmark market estimates and forecasts, 2021 to 2033 (USD Million)
  • 9.4.7. Sweden
    • 9.4.7.1. Key country dynamics
    • 9.4.7.2. Regulatory framework
    • 9.4.7.3. Competitive scenario
    • 9.4.7.4. Sweden market estimates and forecasts, 2021 to 2033 (USD Million)
  • 9.4.8. Norway
    • 9.4.8.1. Key country dynamics
    • 9.4.8.2. Regulatory framework
    • 9.4.8.3. Competitive scenario
    • 9.4.8.4. Norway market estimates and forecasts, 2021 to 2033 (USD Million)
  • 9.4.9. Russia
    • 9.4.9.1. Key country dynamics
    • 9.4.9.2. Regulatory framework
    • 9.4.9.3. Competitive scenario
    • 9.4.9.4. Russia market estimates and forecasts, 2021 to 2033 (USD Million)
  • 9.4.10. Netherlands
    • 9.4.10.1. Key country dynamics
    • 9.4.10.2. Regulatory framework
    • 9.4.10.3. Competitive scenario
    • 9.4.10.4. Netherlands market estimates and forecasts, 2021 to 2033 (USD Million)
  • 9.4.11. Switzerland
    • 9.4.11.1. Key country dynamics
    • 9.4.11.2. Regulatory framework
    • 9.4.11.3. Competitive scenario
    • 9.4.11.4. Switzerland market estimates and forecasts, 2021 to 2033 (USD Million)
• 9.5. Asia Pacific
  • 9.5.1. Japan
    • 9.5.1.1. Key country dynamics
    • 9.5.1.2. Regulatory framework
    • 9.5.1.3. Competitive scenario
    • 9.5.1.4. Japan market estimates and forecasts, 2021 to 2033 (USD Million)
  • 9.5.2. China
    • 9.5.2.1. Key country dynamics
    • 9.5.2.2. Regulatory framework
    • 9.5.2.3. Competitive scenario
    • 9.5.2.4. China market estimates and forecasts, 2021 to 2033 (USD Million)
  • 9.5.3. India
    • 9.5.3.1. Key country dynamics
    • 9.5.3.2. Regulatory framework
    • 9.5.3.3. Competitive scenario
    • 9.5.3.4. India market estimates and forecasts, 2021 to 2033 (USD Million)
  • 9.5.4. South Korea
    • 9.5.4.1. Key country dynamics
    • 9.5.4.2. Regulatory framework
    • 9.5.4.3. Competitive scenario
    • 9.5.4.4. South Korea market estimates and forecasts, 2021 to 2033 (USD Million)
  • 9.5.5. Thailand
    • 9.5.5.1. Key country dynamics
    • 9.5.5.2. Regulatory framework
    • 9.5.5.3. Competitive scenario
    • 9.5.5.4. Thailand market estimates and forecasts, 2021 to 2033 (USD Million)
  • 9.5.6. Australia
    • 9.5.6.1. Key country dynamics
    • 9.5.6.2. Regulatory framework
    • 9.5.6.3. Competitive scenario
    • 9.5.6.4. Australia market estimates and forecasts, 2021 to 2033 (USD Million)
  • 9.5.7. Singapore
    • 9.5.7.1. Key country dynamics
    • 9.5.7.2. Regulatory framework
    • 9.5.7.3. Competitive scenario
    • 9.5.7.4. Singapore market estimates and forecasts, 2021 to 2033 (USD Million)
  • 9.5.8. Philippines
    • 9.5.8.1. Key country dynamics
    • 9.5.8.2. Regulatory framework
    • 9.5.8.3. Competitive scenario
    • 9.5.8.4. Philippines market estimates and forecasts, 2021 to 2033 (USD Million)
  • 9.5.9. Malaysia
    • 9.5.9.1. Key country dynamics
    • 9.5.9.2. Regulatory framework
    • 9.5.9.3. Competitive scenario
    • 9.5.9.4. Malaysia market estimates and forecasts, 2021 to 2033 (USD Million)
  • 9.5.10. Indonesia
    • 9.5.10.1. Key country dynamics
    • 9.5.10.2. Regulatory framework
    • 9.5.10.3. Competitive scenario
    • 9.5.10.4. Indonesia market estimates and forecasts, 2021 to 2033 (USD Million)
• 9.6. Latin America
  • 9.6.1. Brazil
    • 9.6.1.1. Key country dynamics
    • 9.6.1.2. Regulatory framework
    • 9.6.1.3. Competitive scenario
    • 9.6.1.4. Brazil market estimates and forecasts, 2021 to 2033 (USD Million)
  • 9.6.2. Argentina
    • 9.6.2.1. Key country dynamics
    • 9.6.2.2. Regulatory framework
    • 9.6.2.3. Competitive scenario
    • 9.6.2.4. Argentina market estimates and forecasts, 2021 to 2033 (USD Million)
  • 9.6.3. Mexico
    • 9.6.3.1. Key country dynamics
    • 9.6.3.2. Regulatory framework
    • 9.6.3.3. Competitive scenario
    • 9.6.3.4. Mexico market estimates and forecasts, 2021 to 2033 (USD Million)
• 9.7. MEA
  • 9.7.1. South Africa
    • 9.7.1.1. Key country dynamics
    • 9.7.1.2. Regulatory framework
    • 9.7.1.3. Competitive scenario
    • 9.7.1.4. South Africa market estimates and forecasts, 2021 to 2033 (USD Million)
  • 9.7.2. Saudi Arabia
    • 9.7.2.1. Key country dynamics
    • 9.7.2.2. Regulatory framework
    • 9.7.2.3. Competitive scenario
    • 9.7.2.4. Saudi Arabia market estimates and forecasts, 2021 to 2033 (USD Million)
  • 9.7.3. UAE
    • 9.7.3.1. Key country dynamics
    • 9.7.3.2. Regulatory framework
    • 9.7.3.3. Competitive scenario
    • 9.7.3.4. UAE market estimates and forecasts, 2021 to 2033 (USD Million)
  • 9.7.4. Kuwait
    • 9.7.4.1. Key country dynamics
    • 9.7.4.2. Regulatory framework
    • 9.7.4.3. Competitive scenario
    • 9.7.4.4. Kuwait market estimates and forecasts, 2021 to 2033 (USD Million)
  • 9.7.5. Turkey
    • 9.7.5.1. Key country dynamics
    • 9.7.5.2. Regulatory framework
    • 9.7.5.3. Competitive scenario
    • 9.7.5.4. Turkey market estimates and forecasts, 2021 to 2033 (USD Million)
  • 9.7.6. Iran
    • 9.7.6.1. Key country dynamics
    • 9.7.6.2. Regulatory framework
    • 9.7.6.3. Competitive scenario
    • 9.7.6.4. Iran market estimates and forecasts, 2021 to 2033 (USD Million)
  • 9.7.7. Israel
    • 9.7.7.1. Key country dynamics
    • 9.7.7.2. Regulatory framework
    • 9.7.7.3. Competitive scenario
    • 9.7.7.4. Israel market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Participant Overview
• 10.2. Company Market Position Analysis of Overall Digital Pathology Solution Providers
• 10.3. Company Market Position Analysis of AI-enabled Digital Pathology Solution Providers
• 10.4. Vendor Landscape
  • 10.4.1. List of Distributors
• 10.5. Company Market Share Analysis, 2025
• 10.6. Company Categorization
• 10.7. Strategy Mapping
• 10.8. Company Profiles of Overall Digital Pathology Solution Providers
  • 10.8.1. Leica Biosystems Nussloch GmbH (Danaher)
    • 10.8.1.1. Overview
    • 10.8.1.2. Financial performance
    • 10.8.1.3. Product benchmarking
    • 10.8.1.4. Strategic initiatives
  • 10.8.2. Hamamatsu Photonics, Inc.
    • 10.8.2.1. Overview
    • 10.8.2.2. Financial performance
    • 10.8.2.3. Product benchmarking
    • 10.8.2.4. Strategic initiatives
  • 10.8.3. Koninklijke Philips N.V.
    • 10.8.3.1. Overview
    • 10.8.3.2. Financial performance
    • 10.8.3.3. Product benchmarking
    • 10.8.3.4. Strategic initiatives
  • 10.8.4. Olympus Corporation
    • 10.8.4.1. Overview
    • 10.8.4.2. Financial performance
    • 10.8.4.3. Product benchmarking
    • 10.8.4.4. Strategic initiatives
  • 10.8.5. F. Hoffmann-La Roche Ltd.
    • 10.8.5.1. Overview
    • 10.8.5.2. Financial performance
    • 10.8.5.3. Product benchmarking
    • 10.8.5.4. Strategic initiatives
  • 10.8.6. Mikroscan Technologies, Inc.
    • 10.8.6.1. Overview
    • 10.8.6.2. Financial performance
    • 10.8.6.3. Product benchmarking
    • 10.8.6.4. Strategic initiatives
  • 10.8.7. Epredia (3DHISTECH Ltd.)
    • 10.8.7.1. Overview
    • 10.8.7.2. Financial performance
    • 10.8.7.3. Product benchmarking
    • 10.8.7.4. Strategic initiatives
  • 10.8.8. Visiopharm A/S
    • 10.8.8.1. Overview
    • 10.8.8.2. Financial performance
    • 10.8.8.3. Product benchmarking
    • 10.8.8.4. Strategic initiatives
  • 10.8.9. Huron Technologies International Inc.
    • 10.8.9.1. Overview
    • 10.8.9.2. Financial performance
    • 10.8.9.3. Product benchmarking
    • 10.8.9.4. Strategic initiatives
  • 10.8.10. ContextVision AB
    • 10.8.10.1. Overview
    • 10.8.10.2. Financial performance
    • 10.8.10.3. Product benchmarking
    • 10.8.10.4. Strategic initiatives
  • 10.8.11. CellaVision
    • 10.8.11.1. Overview
    • 10.8.11.2. Financial performance
    • 10.8.11.3. Product benchmarking
    • 10.8.11.4. Strategic initiatives
  • 10.8.12. HANGZHOU ZHIWEI INFORMATION TECHNOLOGY CO. LTD. (MORPHOGO)
    • 10.8.12.1. Overview
    • 10.8.12.2. Financial performance
    • 10.8.12.3. Product benchmarking
    • 10.8.12.4. Strategic initiatives
  • 10.8.13. West Medica Produktions- und Handels- GmbH (West Medica)
    • 10.8.13.1. Overview
    • 10.8.13.2. Financial performance
    • 10.8.13.3. Product benchmarking
    • 10.8.13.4. Strategic initiatives
  • 10.8.14. aetherAI
    • 10.8.14.1. Overview
    • 10.8.14.2. Financial performance
    • 10.8.14.3. Product benchmarking
    • 10.8.14.4. Strategic initiatives
  • 10.8.15. IBEX (IBEX MEDICAL ANALYTICS)
    • 10.8.15.1. Overview
    • 10.8.15.2. Financial performance
    • 10.8.15.3. Product benchmarking
    • 10.8.15.4. Strategic initiatives
  • 10.8.16. SigTuple Technologies Private Limited Morphle Labs, Inc
    • 10.8.16.1. Overview
    • 10.8.16.2. Financial performance
    • 10.8.16.3. Product benchmarking
    • 10.8.16.4. Strategic initiatives
  • 10.8.17. Morphle Labs, Inc
    • 10.8.17.1. Overview
    • 10.8.17.2. Financial performance
    • 10.8.17.3. Product benchmarking
    • 10.8.17.4. Strategic initiatives
  • 10.8.18. Bionovation Biotech, Inc.
    • 10.8.18.1. Overview
    • 10.8.18.2. Financial performance
    • 10.8.18.3. Product benchmarking
    • 10.8.18.4. Strategic initiatives
  • 10.8.19. Scopio labs
    • 10.8.19.1. Overview
    • 10.8.19.2. Financial performance
    • 10.8.19.3. Product benchmarking
    • 10.8.19.4. Strategic initiatives
  • 10.8.20. Inspirata, Inc
    • 10.8.20.1. Overview
    • 10.8.20.2. Financial performance
    • 10.8.20.3. Product benchmarking
    • 10.8.20.4. Strategic initiatives
  • 10.8.21. Path Hub
    • 10.8.21.1. Overview
    • 10.8.21.2. Financial performance
    • 10.8.21.3. Product benchmarking
    • 10.8.21.4. Strategic initiatives
  • 10.8.22. Sectra AB
    • 10.8.22.1. Overview
    • 10.8.22.2. Financial performance
    • 10.8.22.3. Product benchmarking
    • 10.8.22.4. Strategic initiatives
  • 10.8.23. Agfa-Gevaert Group
    • 10.8.23.1. Overview
    • 10.8.23.2. Financial performance
    • 10.8.23.3. Product benchmarking
    • 10.8.23.4. Strategic initiatives
  • 10.8.24. OptraScan
    • 10.8.24.1. Overview
    • 10.8.24.2. Financial performance
    • 10.8.24.3. Product benchmarking
    • 10.8.24.4. Strategic initiatives
  • 10.8.25. Agilent Technologies, Inc.
    • 10.8.25.1. Overview
    • 10.8.25.2. Financial performance
    • 10.8.25.3. Product benchmarking
    • 10.8.25.4. Strategic initiatives
  • 10.8.26. KFBIO
    • 10.8.26.1. Overview
    • 10.8.26.2. Financial performance
    • 10.8.26.3. Product benchmarking
    • 10.8.26.4. Strategic initiatives
• 10.9. Company Profiles of AI-enabled Digital Pathology Solution Providers
  • 10.9.1. Aiosyn
    • 10.9.1.1. Overview
    • 10.9.1.2. Financial performance
    • 10.9.1.3. Product benchmarking
    • 10.9.1.4. Strategic initiatives
  • 10.9.2. Proscia Inc.
    • 10.9.2.1. Overview
    • 10.9.2.2. Financial performance
    • 10.9.2.3. Product benchmarking
    • 10.9.2.4. Strategic initiatives
  • 10.9.3. EVIDENT
    • 10.9.3.1. Overview
    • 10.9.3.2. Financial performance
    • 10.9.3.3. Product benchmarking
    • 10.9.3.4. Strategic initiatives
  • 10.9.4. Aignostics, Inc.
    • 10.9.4.1. Overview
    • 10.9.4.2. Financial performance
    • 10.9.4.3. Product benchmarking
    • 10.9.4.4. Strategic initiatives
  • 10.9.5. Aiforia/ Aiforia Technologies PLC
    • 10.9.5.1. Overview
    • 10.9.5.2. Financial performance
    • 10.9.5.3. Product benchmarking
    • 10.9.5.4. Strategic initiatives
  • 10.9.6. Qritive
    • 10.9.6.1. Overview
    • 10.9.6.2. Financial performance
    • 10.9.6.3. Product benchmarking
    • 10.9.6.4. Strategic initiatives
  • 10.9.7. Mindpeak GmbH
    • 10.9.7.1. Overview
    • 10.9.7.2. Financial performance
    • 10.9.7.3. Product benchmarking
    • 10.9.7.4. Strategic initiatives
  • 10.9.8. Dedalus S.p.A
    • 10.9.8.1. Overview
    • 10.9.8.2. Financial performance
    • 10.9.8.3. Product benchmarking
    • 10.9.8.4. Strategic initiatives
  • 10.9.9. Gestalt
    • 10.9.9.1. Overview
    • 10.9.9.2. Financial performance
    • 10.9.9.3. Product benchmarking
    • 10.9.9.4. Strategic initiatives
  • 10.9.10 CGI Inc. Overview
    • 10.9.10.1. Financial performance
    • 10.9.10.2. Product benchmarking
    • 10.9.10.3. Strategic initiatives